Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01889 (ankylosing spondylitis)
 5,717 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The purpose of this study was to evaluate the results of the Thrust Plate Prosthesis as a treatment option for osteoarthritis of the hip in young patients. Of the fifty patients (63 hips) reviewed, 31 (62%) were males and 19 (38%) females. Pre-operative diagnosis included primary osteoarthritis (23), developmental dysplasia (8), avascular necrosis (7), Perthes (4), post-traumatic arthritis (3), rheumatoid arthritis (2), ankylosing spondylitis (1), psoriatic arthropathy (1) and slipped upper femoral epiphysis (1). All components were implanted uncemented with metal-on-metal articulation. The average follow-up was 4.04 years (range 12 months-8.5 years). The mean age of the patients was 42.3 years (range 21-57 years). The mean pre-operative Harris Hip Score was 41.9 (range 12-89) and at final follow-up 89.91 (range 41-100). In 25 hips with > or = 5 yr follow-up, the average HHS at final follow-up was 84.5 (range 50-100). Complications included dislocation (2), transient sciatic nerve palsy (1), discomfort from lateral strap (2), implantation of wrong femoral head (1), revision (3 = 4.76%) and implant loosening (4) (6.35%). The thrust plate prosthesis is a useful alternative in young patients with hip arthritis and the results are comparable with other uncemented hip replacements. The added advantage is preservation of the proximal femoral bone stock, which can prove useful in future revisions.
 ...
PMID:Early results with the thrust plate prosthesis in young patients with osteoarthritis of the hip. 1615 52

A retrospective study was performed in patients with ankylosing spondylitis (AS) from south China, to investigate the efficacy and safety of infliximab after total hip arthroplasty (THA). Thirty-two AS patients were divided into two groups. The treatmen group recieved infliximab at four weeks after unilateral THA (11 patients) and were compare to a control group (21 patients). Patients in the control group were treated with traditional medications. Clinical assessment, laboratory examinations, and x-rays were performed pre- and postoperatively. The BASDAI score decreased more in the infliximab group at six and 12 months after THA, as did the CRP and ESR. The contralateral hips without arthroplasty of patients in the infliximab group improved significantly compared to the control group, in terms of Harris score (HHS), range of motion (ROM) and VAS. However, the hips with an arthroplasty in the control group had a better prognosis than those without arthroplasty of the infliximab group. Hips with arthroplasty in the infliximab group achieved better improvement of HHS than hips without arthroplasty in the control group, but not for ROM and pain relief. No radiological evidence of prosthetic loosening was found in either group. There was no significant difference of the incidence of adverse events between the two groups. Compared with THA, AS patients using infliximab only did not obtain as good an outcome. Infliximab was shown to be safe and could be effective to improve hip function and systemic symptoms.
...
PMID:The efficacy and safety of infliximab used in patients with ankylosing spondylitis after unilateral total hip arthroplasty. 2387 8